Sugi Predict

Sugi Predict / Compounds / SCHEMBL30658672

SCHEMBL30658672

SCHEMBL30658672

O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 20/20 1.00
▸ BCL2L1 Q07817 17/20 1.00
▸ CYP3A4 P08684 1/20 0.83
▸ CYP2C9 P11712 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24774453 1.00 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL30658675 1.00 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL24775021 1.00 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL24775756 0.95 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL30658671 0.95 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL24774722 0.95 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL30658633 0.95 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9
SCHEMBL31525155 0.94 BCL2 (1.00) BCL2BCL2L1
SCHEMBL24775647 0.94 BCL2 (1.00) BCL2BCL2L1
SCHEMBL24776076 0.93 BCL2 (1.00) BCL2BCL2L1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522169-A1 METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR BeiGene Switzerland GmbH (CH) 2025-03-19 — — EP claimed
WO-2023218410-A1 METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR BEIGENE SWITZERLAND GMBH (CH) 2023-11-16 — — WO claimed
EP-4522169-A1 METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR BeiGene Switzerland GmbH (CH) 2025-03-19 — — EP disclosed
WO-2023218410-A1 METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR BEIGENE SWITZERLAND GMBH (CH) 2023-11-16 — — WO disclosed
Send feedback